Effects of chronic stavudine exposure on liver, pancreas and kidneys of pregnant rats and their fetuses: Morphological and biochemical aspects

Barreto, Regina Lúcia Braga; Soares, José Maria; Simões, Ricardo Santos; Maciel, Gustavo Arantes Rosa; Simões, Manuel de Jesus; Kulay, L

doi:10.1016/j.ejogrb.2005.12.027

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experience with stavudine in pregnancy has been largely limited to animal studies, with one small clinical trial in which women receiving stavudine as part of a PMTCT regimen experienced no significant toxicity 8, 9. Extensive use of stavudine in non-pregnant women in Africa has revealed high rates of mitochondrial toxicity, with overweight women particularly at risk for symptomatic and life-threatening lactic acidosis 10-12.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Initiating Highly Active Antiretroviral Therapy in an Integrated Antenatal and HIV Clinic in Johannesburg, South Africa

Black

Hoffman²,

Sugar³

et al. 2008

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Objective To describe the safety and efficacy of highly active antiretroviral therapy (HAART) in pregnant women treated in an integrated antenatal antiretroviral programme (ANC ARV). Methods A retrospective analysis was performed on patients attending the ANC ARV from August 2004 through February 2007. Results Data was collected on 689 treatment-na誰ve pregnant women initiated on HAART. The mean age was 29.2 years. The mean baseline CD4+ count was 154 cells/uL and mean baseline HIV viral load was 101,561 copies/ml. Tuberculosis was the most prevalent presenting opportunistic infection (7.7%). Stavudine, lamivudine, and nevirapine were initiated in 82% of women with the most frequent adverse drug reaction being nevirapine-associated skin rash (3.5%). Mean gestational age at HAART initiation was 27 weeks. Among women with follow-up data, 80% gained 50 or more CD4 cells/uL, and 80.5% achieved viral suppression to <1000 copies/ml. Of 302 mother/infant pairs who completed postnatal follow-up, the HIV transmission rate was 5%. In women who received more than seven weeks of HAART during pregnancy, transmission was 0.3%. Conclusions Within the ANC ARV programme, initiating pregnant women on HAART was feasible, safe, and effective. Advanced gestational age at treatment initiation and loss to follow-up emerge as important challenges in this population.

show abstract

Section: Discussionmentioning

confidence: 99%